North, I often wonder if Amarin and Pfizer have an informal agreement that they will talk at some point about a deal, but that Pfizer needs them to achieve certain "milestones" for that to happen (ie. approvals in Europe, HN lawsuit, etc.).
My guess is that the Du ruling has really kept most BP's away.
The other open question is, how many BP's have CVD experts that fall in the Nissen camp vs. the Bhatt camp...
Does anyone else see a potential intersection between Vascepa use in Kaiser's Mitigate trial and the PFE Covid, flu vaccines shown in PFE slides 125-127?
Market Data 
Markets 
AI
